Companion Diagnostics and IVDs: Regulatory Interfaces with Drug Development Companion Diagnostics and IVDs: Regulatory Interfaces with Drug Development In the evolving landscape of healthcare, the integration of diagnostics with therapeutics has become paramount. Companion diagnostics (CDx) serve as critical tools that guide the use of specific therapeutic products, particularly in areas such as oncology and personalized medicine. The regulatory framework surrounding CDx, In Vitro Diagnostics (IVDs), and Software as a Medical Device (SaMD) presents unique challenges and opportunities for regulatory affairs professionals in the pharmaceutical and biotechnology sectors. This article provides an in-depth understanding of the regulations, guidelines, and agency…

Designing Drug–Diagnostic Co-Development Programs for Targeted Therapies Designing Drug–Diagnostic Co-Development Programs for Targeted Therapies Regulatory Affairs (RA) plays a critical role in the development and approval of targeted therapies, particularly when there is a need for companion diagnostics. As the integration of pharmaceuticals and diagnostics evolves, so does the regulatory framework that governs their development and approval. This article outlines the key regulations, guidelines, and strategic considerations necessary for designing effective drug-diagnostic co-development programs, specifically in the context of service pharmacovigilance and special product regulatory pathways. Context The convergence of drug development and diagnostic innovation has prompted the emergence of…

IVDR, MDR and FDA Requirements for Companion Diagnostic Approvals IVDR, MDR and FDA Requirements for Companion Diagnostic Approvals In the rapidly evolving landscape of pharmaceuticals and biotechnology, the intersection of regulatory affairs and medical device compliance is of paramount importance, particularly concerning companion diagnostics. This article serves as a comprehensive regulatory explainer manual focused on the regulatory requirements and pathways governing In Vitro Diagnostic Regulation (IVDR) and the Medical Device Regulation (MDR) within the EU, alongside FDA expectations in the United States. Context Companion diagnostics are medical devices or in vitro diagnostics that provide essential information for the safe and…

Clinical Evidence Expectations for Predictive and Prognostic Diagnostics Clinical Evidence Expectations for Predictive and Prognostic Diagnostics In the rapidly evolving landscape of personalized medicine, predictive and prognostic diagnostics play a crucial role in enhancing patient outcomes and streamlining treatment protocols. As professionals in Regulatory Affairs (RA), understanding the complex interplay of regulations and guidelines within this domain is essential. This article delves into the regulatory environment governing companion diagnostics, in vitro diagnostics (IVDs), and software as a medical device (SaMD), specifically in the context of clinical evidence expectations across the US, UK, and EU. Through a structured exploration, we will…

SaMD and Software-Enabled Diagnostics: Regulatory Basics for RA Teams SaMD and Software-Enabled Diagnostics: Regulatory Basics for RA Teams In the rapidly evolving landscape of healthcare technology, Software as a Medical Device (SaMD) and software-enabled diagnostics play a crucial role in modern patient care. This article aims to provide a comprehensive understanding of the key regulatory considerations surrounding SaMD and diagnostic software within the context of global regulatory affairs, specifically focusing on the US, UK, and EU markets. Regulatory Affairs Context As healthcare companies increasingly rely on technology to enhance diagnostics and treatment, SaMD and software-enabled diagnostics have emerged as significant…

Classification and Risk-Based Frameworks for IVDs and SaMD in US, EU and UK Classification and Risk-Based Frameworks for IVDs and SaMD in US, EU and UK Context In the realm of biomedical innovation, In Vitro Diagnostics (IVDs) and Software as a Medical Device (SaMD) represent crucial segments that necessitate comprehensive regulatory oversight. These technologies not only facilitate patient diagnosis and treatment but also intersect with various regulatory frameworks established by key authorities such as the FDA in the US, the EMA in the EU, and the MHRA in the UK. This article aims to dissect the relevant regulations and guidelines…

Case Studies: Companion Diagnostic Approvals Linked to Oncology Products Case Studies: Companion Diagnostic Approvals Linked to Oncology Products Introduction to Companion Diagnostics and Regulatory Landscape The convergence of diagnostics and therapeutics in oncology has led to the emergence of companion diagnostics (CDx), which are essential for the safe and effective use of targeted therapies. As these products often operate at the interface between therapeutics and devices, understanding the regulatory context surrounding their development, approval, and commercialization is critical for Regulatory Affairs (RA) professionals. Regulatory requirements differ significantly across regions such as the United States, European Union, and United Kingdom, necessitating…

Lab-Developed Tests, Central Labs and Global Regulatory Complexity Lab-Developed Tests, Central Labs and Global Regulatory Complexity This article provides a comprehensive overview of the regulatory landscape concerning Lab-Developed Tests (LDTs), Central Laboratories, and the complexities of navigating global regulations. With a focus on the United States, European Union, and United Kingdom, this guide aims to assist Regulatory Affairs (RA), CMC, and Labelling teams within pharmaceutical and biotech organizations as they work within this critical area of diagnostics. Understanding the interplay between pharmacovigilance solutions and the regulations governing these advanced therapies is essential for successful product development and commercialization. Context Lab-Developed…

Labeling and IFU Alignment Between Drug and Companion Diagnostic Labeling and IFU Alignment Between Drug and Companion Diagnostic The intersection of regulatory affairs and compliance within the framework of special product categories, particularly drug-device combinations and companion diagnostics, represents a significant challenge and opportunity for pharmaceutical and biotechnology companies. With the advent of personalized medicine, a thorough understanding of regulatory expectations and guidelines is critical for success in this evolving landscape. Context Companion diagnostics (CDx) play a pivotal role in the applicable therapeutic landscape by enabling healthcare professionals to determine the efficacy of a drug in specific patient populations. The…

Post-Market Surveillance and Performance Follow-Up for IVDs and SaMD Post-Market Surveillance and Performance Follow-Up for IVDs and SaMD Context The regulatory landscape for In Vitro Diagnostics (IVDs) and Software as a Medical Device (SaMD) is continually evolving. Regulatory Affairs (RA) professionals play a critical role in navigating this complex environment to ensure compliance with post-market surveillance obligations. This article outlines the essential aspects of compliance regulatory affairs with a focus on the framework governing post-market activities for IVDs and SaMD in the US, UK, and EU. Legal/Regulatory Basis Post-market surveillance (PMS) and performance follow-up activities for IVDs and SaMD are…